HC Wainwright & Co. Initiates Coverage On Genelux With Buy Rating, Announces Price Target of $35
Genelux Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Genelux Corp. (GNLX), Calliditas Therapeutics (CALT)
Genelux Analyst Ratings
Benchmark Company Adjusts Genelux Price Target to $30 From $38, Maintains Speculative Buy Rating
Genelux Analyst Ratings
Benchmark Raises Price Target on Genelux to $38 From $10, Maintains Speculative Buy Rating
Benchmark Maintains Speculative Buy on Genelux, Raises Price Target to $38
Genelux (GNLX.US) was covered by Brookline Capital for the first time, gave it a holding rating, and the target price was $25.00.
Brookline Capital Initiates Coverage On Genelux With Hold Rating, Announces Price Target of $25
Benchmark Initiates Coverage On Genelux With Speculative Buy Rating, Announces Price Target of $10
No Data